Fol News

Tutti gli approfondimenti
Tutte le notizie

DNDN - Dendreon Corporation (NASDAQ:DNDN)

Stato
Chiusa ad ulteriori risposte.
visto e considerato che il titolo ha oscillazioni notevoli durante la seduta, questo 3ad avra' la sua fine all'apertura di domani.

IL GAIN E' STATO FATTO da 5 a 25, ora e' una scommessa, se il 15 e' un si saranno gioie, altrimenti.........

giocare intraday mi sembra un pochino pericoloso.

In ogni caso un cippino l'ho anch'io da 16
 
The implied volatility in the options of Dendreon is still pumped to extremes with readings above the 200% level. The company recently received approval to proceed with testing for marketing its Provenge vaccine for treating prostrate cancer, even though the initial trials were slightly disappointing. Investors must be bracing for some more news regarding the efficacy of the drug. But one option trade suggests someone is betting that news will not come before the May 18 expiration. The notable trade was the sale of the May 17.50 put and 30 call 16,000 times each. The net credit for the strangle was $9.20, or $14.7 million, for the 16,000 contracts. That's a big bet that the stock remains in the $12 range for the next nine sessions. Of course, the breakeven points are $8.30 and $39.20, a $31 price range. That's pretty wide on a stock currently...

PER OPTION, INTENDO C.W ?? O ALTRO?
 
Gulliver13 ha scritto:
The implied volatility in the options of Dendreon is still pumped to extremes with readings above the 200% level. The company recently received approval to proceed with testing for marketing its Provenge vaccine for treating prostrate cancer, even though the initial trials were slightly disappointing. Investors must be bracing for some more news regarding the efficacy of the drug. But one option trade suggests someone is betting that news will not come before the May 18 expiration. The notable trade was the sale of the May 17.50 put and 30 call 16,000 times each. The net credit for the strangle was $9.20, or $14.7 million, for the 16,000 contracts. That's a big bet that the stock remains in the $12 range for the next nine sessions. Of course, the breakeven points are $8.30 and $39.20, a $31 price range. That's pretty wide on a stock currently...

PER OPTION, INTENDO C.W ?? O ALTRO?
Clicca per espandere...
http://finance.yahoo.com/q/op?s=dndn
i covered warrant esistono solo da noi
 
SEATTLE, May 9 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN - News) today announced that it received a Complete Response Letter, commonly referred to as an "approvable" letter, on May 8, 2007 from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for PROVENGE (sipuleucel-T) for the treatment of asymptomatic, metastatic, androgen-independent (also known as hormone refractory) prostate cancer. The FDA has requested additional clinical data in support of the efficacy claim contained in the BLA. The Company is seeking a clarification from the FDA as to the nature of the data that is being requested. The FDA has also requested additional information with respect to the chemistry, manufacturing and controls (CMC) section of the BLA, which the Company believes it can supply to the FDA in a timely manner. "Given our strong belief in the survival benefit and safety profile of PROVENGE, coupled with the positive outcome of the Advisory Committee meeting, we are disappointed that this decision will cause a delay in the availability of PROVENGE for patients who suffer from advanced prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are committed to working closely with the FDA to resolve these questions in a timely and efficient manner to bring PROVENGE to patients with advanced prostate cancer who currently have few appealing treatment options."


tutti a casa
 
May 9 (Reuters) - Dendreon Corp. (DNDN.O: Quote, Profile , Research) said the U.S. Food and Drug Administration has requested additional clinical data regarding its Biologics License Application for Provenge, its treatment for prostate cancer.

The company said this would cause a delay in the availability of the drug. (Reporting by Anup Roy in Bangalore)


Reuters Pictures

Editors Choice: Best pictures
from the last 24 hours.
View Slideshow

by http://yahoo.reuters.com/news/artic...05-09_09-48-49_WNAS0478&type=comktNews&rpc=44
 
non si scherza con le istituzioni e con i soldi!!

ragazzi si salvi chi puo'!
 
solo 2000 pezzi x ora xò scambia a 11$...
una belle incul...
fortuna che ero uscito x entrar su idmi... speriamo sia altra musica :'(
 
LONDON, May 9 (Reuters) - Plans by U.S. biotech company Dendreon Corp. (DNDN.O: Quote, Profile , Research) to market a pioneering therapeutic cancer vaccine were dealt a blow on Wednesday when U.S. regulators demanded more data before approving it.

Dendreon said the Food and Drug Administration wanted additional clinical data on Provenge in support of its efficacy claim and had also requested more information about chemistry, manufacturing and controls.

Provenge is a therapeutic cancer vaccine designed to stimulate the body's immune system to fight an existing cancer. It differs from traditional vaccines that prevent infections in people not yet sick. "We are disappointed that this decision will cause a delay in the availability of Provenge for patients who suffer from advanced prostate cancer," Mitchell Gold, the Seattle-based company's president and chief executive, said in a statement.


Reuters Pictures

Editors Choice: Best pictures
from the last 24 hours.
View Slideshow

An FDA advisory panel said in March that Provenge appeared reasonably safe, and there was "substantial evidence" of its benefits. But investors have been wary about the product because two Dendreon studies failed to meet their main goal of slowing the progress of advanced prostate cancer, though one analysis found patients treated lived about 4.5 months longer.

Prostate cancer will be diagnosed in about 218,000 U.S. men in 2007 and kill 27,000, the American Cancer Society estimates.

Provenge was studied in men with advanced prostate cancer that had stopped responding to hormone therapy but was not causing pain.

If Provenge does eventually win FDA approval, it could give a boost to the emerging field of therapeutic cancer vaccines. Several companies including GlaxoSmithKline Plc (GSK.L: Quote, Profile , Research) are working on similar products for a variety of tumour types. (Additional reporting by Anup Roy in Bangalore)
 
Dendreon (DNDN-NASDAQ) has only up to 4 full trading before that May 15 FDA review date. The funny thing here is that the options have actually become more expensive since reporting on this last week. The current $17.50 straddle would run $12.90 for the May expiration on the Put and Call strike prices.

Even going way out on the strikes is far from a bargain: The May $25.00 Calls went out at $3.80 premium today; and the May $10.00 Puts went out at $2.10. Neither of those are cheap at a $17.74 close for Dendreon today. The funniest thing is that the time value portion of the premiums will not compress drastically each day ahead of the FDA event as more and more traders have little to no choice but to put on certain hedging transactions after the last move that Dendreon made on receipt of the panel backing for provenge. If this was a normal option with no event risk it would theoretically lose up to 1/8 of the value each day from here, but the event risk going into next Wednesday will keep these premiums high until after the formal FDA decision.

There is still a ways to go before (5 trading days) this one is a known verdict.

Jon C. Ogg
May 8, 2007

FORSE ESISTE ANCORA UNA POSSIBILITA'!!!
 
la volatilità a questo punto è scontata!!!
Comunque occhi aperti!!!
 
Ehy ragazzi...avete visto il pre-market di DNDN???...le cose non sono andate bene :( , menomale che ne sono restato fuori....almeno per il momento!
Se avete news postate!
 
Ragazzi e se questa fosse una manovra per spazzare tutti i piccoli investitori?In fondo non e' ancora detto che non sara' approvato il 15 Maggio.
 
Giulio35 ha scritto:
Ragazzi e se questa fosse una manovra per spazzare tutti i piccoli investitori?In fondo non e' ancora detto che non sara' approvato il 15 Maggio.
Clicca per espandere...

spazzare non vuol dire abbatere il prezzo del 60% ... suvvia senza rancore .... OK!
 
nasdaq survival ha scritto:
7,5...a questo punto diventa papabile un'entrata...
Clicca per espandere...

:yes: io sono entrato..... :rolleyes:
per me nei giorni a seguire risale :rolleyes:
buona fortuna a tutti :rolleyes:

grease :confused:
 
dentro con oltre 100k....io ci credo!!!
 
Stato
Chiusa ad ulteriori risposte.
Indietro